The pulmonary circulation is a low-resistance, low-pressure, and high-compliance system
that allows the lungs to receive the entire cardiac output. Pulmonary arterial pressure is a …

Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line
treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second …

Background A recent Mendelian randomization (MR) did not support an effect of the lead
interleukin-6 receptor (IL-6 R) variant on risk of pulmonary arterial hypertension (PAH). Thus …

Right ventricular (RV) failure determines the prognosis in pulmonary arterial hypertension
(PAH), but the underlying mechanism is still unclear. Growing evidence has shown that …

Abstract Aims/Introduction The triglyceride‐glucose (TyG) index is a simple and reliable
indicator of insulin resistance, and is associated with the development and poor outcomes of …

Introduction Cell therapy has emerged as an alternative option for chronic lung diseases
with the highest rates of morbidity and mortality rates worldwide. Areas covered This review …

Abstract Background Pulmonary Arterial Hypertension (PAH) is a rare, debilitating, and
potentially fatal disease. This study aims to quantify the economic burden of PAH in Spain …

Background. Endothelium‐mesenchymal transition (EndMT) is a process of phenotypic and
functional transition from activated endothelial cells to mesenchymal cells. Recently, EndMT …

Pulmonary arterial hypertension (PAH) is a rare yet serious progressive disorder that is
currently incurable. This female-predominant disease unfolds as a pan-vasculopathy that …

Filamin A (FLNA) is a high molecular weight cytoskeleton protein important for cell
locomotion. A relationship between FLNA mutations and pulmonary arterial hypertension …